Table 1. Characteristics of patients included in the study.

Patient	Age	Sex	Diagnosis	Treatment (Y/N)	HBsAg (P/N)	HBcAg (P/N)	HBeAg (P/N)	Anti-HBsAg	Anti-HBcAg	Anti-HBeAg	DNA
iDonor 1	44	F	DONOR, cleared HBV	N	N	NA	NA	P	P	NA	NA
iDonor 2	48	F	DONOR, cleared HBV	N	N	NA	NA	P	P	NA	NA
iDonor 3	62	M	DONOR, cleared HBV	N	N	NA	NA	N	P	NA	NA
iDonor 4	56	M	DONOR, cleared HBV	N	N	NA	NA	P	P	NA	NA
iP-BC	49	M	Liver cirrhosis based on chronic HBV infection	Y	P	NA	NA	P	P	NA	<20
iP-BCC1	65	M	HBV liver cirrhosis with HCC	Y	P	NA	NA	N	P	NA	NA
iP-BCC2	54	M	Chronic liver cirrhosis along with HCC	Y	P	NA	NA	N	P	NA	<20
iP-BCC3	68	M	Chronic HBV liver cirrhosis with HCC	Y	P	NA	NA	N	P	NA	<20
iP-BCC4	52	M	HBV liver cirrhosis with multiple HCC	Y	P	NA	N	N	P	P	<20
iP-BCC5	51	M	HBV liver cirrhosis with HCC	Y	P	NA	NA	N	P	NA	<20
iP-BCC6	63	M	HBV liver cirrhosis with HCC	Y	P	N	N	N	P	P	<20
iP-BCC7	61	M	HBV liver cirrhosis with HCC	Y	P	NA	NA	N	P	NA	28
iP-BCC8	53	M	HBV liver cirrhosis with HCC	Y	P	NA	N	N	P	P	<20
iP-BFA	54	F	Acute liver failure based on HBV with Crohn’s disease	N	P	NA	N	N	P	P	<20
iP-BFA2	62	M	Acute liver failure based on HBV	N	P	NA	NA	P	P	NA	NA
iP-BDFA	28	M	Acute liver failure based on HBV and HDV co-infection	N	P	NA	N	NA	P	P	1180
iP-BDFA2	60	F	Acute liver failure based on HBV and HDV co-infection	Y	P	NA	NA	N	P	NA	1080
iP-BDCC	59	M	HCC, HBV co-infected with HDV	Y	P	NA	NA	N	P	P	<20
Patient	Age	Sex	Diagnosis	Treatment (Y/N)	HBsAg (P/N)	HBcAg (P/N)	HBeAg (P/N)	Anti-HBsAg	Anti-HBcAg	Anti-HBeAg	DNA	Nash (Y/N)
CN1	69	F	Nash-HCC	N	N	N	N	N	N	N	NA	Y
CN2	71	M	Nash-HCC	N	N	N	N	N	N	N	NA	Y
CN3	66	F	Nash-HCC	N	N	N	N	N	N	N	NA	Y
CN4	60	F	Nash-HCC	N	N	N	N	N	N	N	NA	Y